ARTICLE | Clinical News
Allogeneic aNK cells: Preliminary Ph II QUILT-3.009 data
January 27, 2017 4:27 AM UTC
Preliminary data from 3 patients with unresectable stage IIIB or IV MCC in the open-label, U.S. Phase II QUILT-3.009 trial showed that 2x109 IV aNK cells/m2 for 2 consecutive days every 2 weeks were w...
BCIQ Company Profiles